Printer Friendly

CYTOGEN INITIATES CLINICAL TRIALS FOR IMAGING NON-SMALL CELL LUNG CANCER

CYTOGEN INITIATES CLINICAL TRIALS FOR IMAGING NON-SMALL CELL LUNG CANCER
 PRINCETON, N.J., Dec. 23 /PRNewswire/ -- CYTOGEN Corporation (NASDAQ: CYTO) today reported the initiation of Phase I human clinical trials for a non-small cell lung cancer imaging product.
 The studies with OncoTc(TM) NSL380 (lung) will initially be conducted at three U.S. hospitals. This product is an integral part of the corporation's broad-based cancer imaging program and strategy to lead the in-vivo cancer imaging market.
 The OncoTc agent is the first product CYTOGEN will evaluate in humans that uses technetium-99m as the diagnostic isotope. It employs a monoclonal antibody (MAb) fragment which the company anticipates will seek out and bind to diseased cells.
 Attached to the fragment is the radioisotope technetium-99m, which following injection, is expected to reveal the extent and location of disease when a patient is scanned with a gamma camera. CYTOGEN said it believes that the MAb fragment is preferable to whole MAbs for imaging lung cancer because the OncoTc conjugate should clear more quickly from background blood pool areas, providing a sharper image of both primary tumors and diseased lymph nodes. Technetium-99m is the isotope chosen for this application because its half-life compares favorably to that of an antibody fragment.
 Non-small cell lung cancer is one of the leading cancers in the United States according to the American Cancer Society. An estimated 130,000 new cases of non-small cell lung cancer will occur in the United States in 1991 and nearly 115,000 people will die from this disease.
 CYTOGEN Corporation is a biopharmaceutical company which has developed proprietary systems for linking drugs and diagnostic agents to monoclonal antibodies in order to optimize the function of the antibody as a delivery vehicle. The first of CYTOGEN Corporation's cancer imaging products has already been approved for sale in five European countries. The company currently has six cancer imaging agents under development and two of these imaging agents, for colorectal and ovarian cancer are awaiting FDA marketing approval. Two cancer therapy agents are also under development.
 /delval/
 -0- 12/23/91
 /CONTACT: Laura Hahn of CYTOGEN, 609-987-8221/
 (CYTO) CO: CYTOGEN Corporation ST: New Jersey IN: MTC SU: PDT


KA -- PH003 -- 4728 12/23/91 09:24 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 23, 1991
Words:370
Previous Article:ALPHA 1 BIOMEDICALS COMPLETES ACQUISITION OF U.S. RIGHTS TO THYMOSIN ALPHA 1 FROM HOFFMANN-LA ROCHE
Next Article:CONSUMERS POWER FILES WITH FEDERAL ENERGY REGULATORY COMMISSION LICENSE APPLICATIONS FOR 11 HYDROELECTRIC GENERATING PLANTS
Topics:


Related Articles
CYTOGEN INITIATES CLINICAL TRIALS FOR IMAGING BREAST CANCER
CYTOGEN INITIATES CLINICAL TRIALS OF THROMBOSCAN(TM), THE WORLD'S FIRST MRU PRODUCT
CYTOGEN AND CYTORAD INITIATE CLINICAL TRIALS OF CANCER THERAPY AGENT
MEDCO RESEARCH'S ATP ANTICANCER DRUG MOVES TO CLINICAL TRIALS
CYTOGEN ACQUIRES RIGHTS TO PAIN RELIEF AGENT FOR BONE CANCER
CYTOGEN REPORTS BUSINESS UPDATE AND SECOND QUARTER RESULTS
Agouron Announces Confirmatory Trial of Oral Anti-Angiogenesis Drug Prinomastat for Treatment of Lung Cancer.
Biomira begins BLP25 cancer vaccine clinical trial phase II lung cancer trial testing Immune Response to higher dose/high frequency vaccine treatment.
Biomira Begins Second Stage of Phase II BLP25 Cancer Vaccine Clinical Trial.
Cell Genesys Reports Further Encouraging Results From Initial Phase I/II Trial Of GVAX(R) Lung Cancer Vaccine.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters